A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

Phase 2

Not yet recruiting

• Conditions: Hepatitis D
• Interventions: Drug: Ursodeoxycholic acid; Drug: Ropeginterferon alfa-2b; Drug: Tenofovir Alafenamide

• Registration Number: NCT05467553
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.

Detailed Description

There will be 2 treatment groups in this study, 15 subjects per group as follows:

Group 1: TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

Group 2: Ursodeoxycholic Acid (UDCA)\* 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

Both groups will have a post-treatment follow-up of 24 weeks.

\*: Dose of Ursodeoxycholic Acid (UDCA) will be determined by weight at Day 1 (TW0) in 2-4 divided doses.

Study Timeline

• Status Verified: 2022-07
• Study First Submitted: 2022-07-15
• Study First Submitted QC: 2022-07-19
• Study First Posted: 2022-07-20
• Last Update Submitted: 2022-12-27
• Last Update Posted: 2022-12-29
• Study Start: 2023-02-24
• Primary Completion: 2025-02-28
• Study Completion: 2025-08-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Positive for HBsAg for at least 6 months, either HBeAg(+) or HBeAg(-), and positive for anti-HDV with detectable HDV RNA and ALT ≥ ULN to ≤ 10X ULN at screening.

2. Interferon treatment naïve.

3. Willing and able to provide written informed consent.

4. Age 20-75 years old; subjects who are over 70 years of age must be in generally good health.

5. Laboratory test results before study entry: WBC ≥ 3,000/mm3; ANC ≥ 1,500/mm3; Platelet ≥ 90,000/mm3; Hemoglobin ≥ 10g/dL; e-GFR ≥ 60mL/min.

6. ECG without clinically significant abnormalities before study entry.

7. Be able to attend all scheduled visits and to comply with all study procedures.

8. Patients with anti-HCV(+) or anti-HIV(+) can be enrolled if:

   1. anti-HCV(+) with undetectable HCV RNA ≥ 3 months.
   2. anti-HIV(+) with undetectable HIV viral load (either with or without Highly Active Anti- Retroviral Therapy, HAART).

Exclusion Criteria

1. Clinically significant illness or surgery that might interfere with study participation.
2. Clinically significant vital sign abnormalities, uncontrolled hypertension, or fever [body temperature >38 degrees Celsius].
3. History of significant alcohol or drug abuse within 6 months prior to the screening visit (alcohol consumption of more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or refusal to abstain from alcohol or illicit drugs throughout the study.
4. Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bi-polar disorder, schizophrenia, suicidal ideation or history of suicidal attempt), neurological, cardiovascular, pulmonary, hematologic, immunologic, autoimmune diseases, thyroid or other endocrine diseases, metabolic (e.g. diabetes mellitus with HbA1C > 8.0%) or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias.
5. Pregnant subject; female subject who are breast feeding or lactating; female subject or the spouse of male subject, with child-bearing potential who is unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices throughout the study.
6. History of severe allergic or hypersensitivity reactions, e.g. hypersensitivity to the active substance or to any of the excipients of ropeginterferon alfa 2b, ursodeoxycholic acid, tenofovir disoproxil fumarate and tenofovir alafenamide.
7. Therapy with any systemic anti-viral treatment, anti-neoplastic, or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug.
8. A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis.
9. Body organ transplant or taking immunosuppressant.
10. Use of an investigational drug within 4 weeks prior to the first dose of the study drug.
11. History of malignancy diagnosed or treated within 5 years prior to screening (except for localized treatment of squamous or non-invasive basal cell skin cancers; cervical carcinoma in situ); cancer survivors not on maintenance therapy within the past 5 years.
12. History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia).
13. Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within 3 months prior to screening.
14. Clinically significant medical conditions known to interfere absorption, distribution, metabolism or excretion of the study drugs.
15. Decompensated liver disease, which includes but not limited to the following: total bilirubin ≥ 2 mg/dL (except in Gilbert syndrome), direct bilirubin ≥ 2X ULN, albumin level < 3.5 g/dL, INR ≥ 1.5; clinical evidence of ascites, liver decompensation, hepatic encephalopathy, oesophageal varices or cirrhosis as identified by ultrasound or any other examination before study entry.
16. Significant steatohepatitis by ultrasound or other examination at the discretion of investigator.
17. Other form of significant chronic liver diseases, except those mentioned above.
18. Significant or major fundoscopic findings at screening including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macu-lar changes.
19. Patients with complete biliary obstruction, chololithiasis, severe pancreatic disease or peptic ulcer.
20. Patients treated by monotherapy of telbivudine/TDF/TAF/adefovir dipivoxil or any other combination therapy with telbivudine/TDF/TAF/adefovir dipivoxil within 1 month prior to screening.
21. Patient who vaccination with any live attenuated vaccine within 1 month prior to screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
TAF and P1101 combination therapy with UDCA	Ursodeoxycholic acid	Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
TAF and P1101 combination therapy with UDCA	Ropeginterferon alfa-2b	Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
TAF and P1101 combination therapy with UDCA	Tenofovir Alafenamide	Ursodeoxycholic Acid (UDCA) 15 mg/kg orally (PO) QD plus TAF 25 mg orally (PO) QD for 60 weeks, with P1101 450 µg subcutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
TAF and P1101 combination therapy without UDCA	Ropeginterferon alfa-2b	TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.
TAF and P1101 combination therapy without UDCA	Tenofovir Alafenamide	TAF 25 mg orally (PO) QD for 60 weeks with P1101 450 µg sub-cutaneously (SC) Q2W add-on at treatment week 12 for 48 weeks.

Primary Outcome Measures

Name	Time	Method
HDV RNA level	Week 60	Decline in HDV RNA ≥ 2 log10 IU/mL at Week 60
ALT level	Week 60	ALT normalization (ALT \< upper limit of normal) at Week 60

Secondary Outcome Measures

Name	Time	Method
Undetectable HDV RNA	Week 60 and Week 84	Undetectable HDV RNA (HDV RNA\< low limit of quantifica-tion) at Week 60 and Week 84
HBsAg level	Week 60 and Week 84	Reduction in HBsAg ≥ 1 log10 IU/mL at Week 60 and Week 84
Undetectable HBsAg	Week 60 and Week 84	HBsAg loss at Week 60 and Week 84
HBsAg and anti-HBs level	Week 60 and Week 84	HBsAg seroconversion (HBsAg loss plus positive anti-HBs) at Week 60 and Week 84
HDV RNA level	Week 84	Decline in HDV RNA ≥ 2 log10 IU/mL at Week 84
ALT level	Week 84	ALT normalization (ALT \< upper limit of normal) at Week 84

Trial Locations

Locations (2)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan

Taipei Medical University Hospital; 🇨🇳 Taipei, Taiwan